Skip to main content
Haesun Choi, MD, Nuclear Medicine, Houston, TX

Haesun Choi MD


Physician

Join to view full profile
  • 1515 Holcombe BlvdHouston, TX 77030

  • Phone+1 713-792-6161

Join Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Haesun Choi, MD is a board certified nuclear medicine physician in Houston, Texas. She is currently licensed to practice medicine in Texas, Alabama, and Iowa. She is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

  • USA Health
    USA HealthResidency, Radiology-Diagnostic, 1987 - 1989
  • University of Iowa Health Care Medical Center
    University of Iowa Health Care Medical CenterResidency, Nuclear Medicine, 1984 - 1987
  • Hanyang University College of Medicine
    Hanyang University College of MedicineClass of 1979

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1992 - 2028
  • IA State Medical License
    IA State Medical License 1984 - 2005
  • IA State Medical License
    IA State Medical License 1984 - 2005
  • AL State Medical License
    AL State Medical License 1988 - 2001
  • Nuclear Medicine
    American Board of Nuclear Medicine Nuclear Medicine
  • Diagnostic Radiology
    American Board of Radiology Diagnostic Radiology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Publications & Presentations

PubMed

Press Mentions

  • Tumor Response Criteria for Assessing Pazopanib First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)
    Tumor Response Criteria for Assessing Pazopanib First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)June 1st, 2020